glp-1 weight loss plateau Struggling with Loss? Here's What to Do Next Before and after GLP-1: what

The long-acting GLP-1 agonists segment held the largest market share of 63% in 2025, driven by the offering of once-weekly dosing, which drastically enhances patient adherence over daily therapies

These obesity medications, such as Glucagon Like Peptide-1 Receptor Agonists (GLP-1 RAs), have gained significant attention for their promising efficacy in achieving weight loss

Ongoing check-ins allow our team to adjust dosing, address concerns, and make sure the plan continues to align with overall wellness goals

In a Chinese phase II trial, mazdutide reduced HbA 1c in a dose-dependent manner by 1.41% to 1.67%, while the placebo groups HbA 1c increased by 0.03% [49]

( 10.1016/S0140-6736(2100213-0) [DOI] [PubMed] [Google Scholar] de Souza AH Tang J Yadev AK Saghafi ST Kibbe CR Linnemann AK Merrins MJ & Davis DB

The slowed gastric emptying that contributes to satiety may also cause prolonged feelings of fullness or discomfort, potentially disrupting normal eating patterns and sleep quality